Identification of differentially expressed genes in salivary adenoid cystic carcinoma cells associated with metastasis

Wei Chen¹, Bing-Yao Liu¹, Xiang Zhang¹, Xiao-Ge Zhao², Gang Cao¹, Zhen Dong¹, Sen-Lin Zhang¹

¹Department of Stomatology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China
²Key Laboratory of Environment and Genes Related to Diseases, Xi’an Jiaotong University College of Medicine, Xi’an, Shaanxi, China

Submitted: 15 October 2014
Accepted: 6 December 2014

Arch Med Sci 2016; 12, 4: 881–888
DOI: 10.5114/aoms.2016.60973
Copyright © 2016 Termedia & Banach

Abstract

Introduction: Salivary adenoid cystic carcinoma (SACC) is a frequent type of salivary gland cancer which is characterized by slow growth but high incidence of distant metastasis. We aimed to identify therapeutic targets which are associated with metastasis of SACC.

Material and methods: Total RNA was isolated from a low metastatic SACC cell line (ACC-2) and a highly metastatic SACC cell line (ACC-M), which was screened from ACC-2 by combination of in vivo selection and cloning in vitro. Then the total RNA was subjected to microarray analysis. Differentially expressed genes (DEGs) were screened from ACC-M compared with ACC-2, followed by Gene Ontology function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Function annotation for DEGs also was performed. A protein-protein interaction network (PPI) was constructed for DEGs.

Results: A total of 1128 DEGs were identified from ACC-M cells compared with ACC-2 cells. Both up- and down-regulated DEGs were enriched in different functions in biological process (BP), cellular component (CC) and molecular function (MF). Additionally, down-regulated DEGs were mainly enriched in “Apoptosis” and “Cytokine-cytokine receptor interaction” pathways which involved IFN-α1, NTRK1 and TGF-β1. In the PPI network, PIK3CA, PTPN11 and PIK3R1 had a number of nodes greater than 10.

Conclusions: Transforming growth factor β1 might play a pivotal role during lung metastasis of SACC and be selected as a candidate target for treatment of metastatic SACC. IFNA1, NTRK1 and PIK3CA were also associated with tumor metastasis.

Key words: adenoid cystic carcinoma, metastasis, function annotation, protein-protein interaction.

Introduction

Salivary adenoid cystic carcinoma (SACC) is a frequent subtype of salivary gland malignancy, which accounts for 25% of malignant tumors in the major salivary glands and 10% of all head and neck carcinomas [1]. Salivary adenoid cystic carcinoma is characterized by slow growth but high incidence of distant metastasis, particularly to the lungs. Distant meta-
sis occurs in 25–50% of patients and commonly in lungs but less commonly in the liver and bone [2, 3]. However, the reason for the invasiveness and metastatic dissemination of SACC remains unclear. Although not well understood for molecular mechanisms of cancer metastasis, angiogenesis might be a possible mechanism involved [4]. Angiogenesis is the development of new blood vessels and an important process occurring in tumor growth and metastasis. The process is intricately regulated by multiple angiogenic cytokines and other factors released by tumor cells in different pathways, such as vascular endothelial growth factor (VEGF), angiopeptin-1, basic fibroblast growth factor, platelet-derived growth factor receptor, stem cell factor receptor (c-Kit), and transforming growth factor-β1 (TGF-β1) [5, 6]. As the most notable angiogenic factor, VEGF has been shown to be highly expressed in SACC, and its expression is associated with tumor size, invasion and metastasis [7–9]. Furthermore, recent studies have indicated that overexpression of inducible nitric oxide synthase and nuclear factor κB could contribute to angiogenesis by up-regulation of VEGF in many cancers [10, 11]. Additionally, c-Kit receptor, also known as CD117, was originally identified as an oncoprotein encoded by a feline sarcoma virus. Its activation would induce diverse intracellular responses such as mitogen-activated protein kinase (MAPK) and phosphoinositide-3 kinase (PI3K/Akt) pathways [12]. Thus, c-Kit regulates blood cell survival and growth control via the aforementioned two pathways. As a result, VEGF and c-Kit have been used as targets of molecule inhibitors for treatment of SACC [13, 14]. Disappointingly, the mechanism of tumorigenesis and metastasis of SACC is not clearly elucidated and therapeutic targets are rare in clinical therapy. Because conventional chemotherapy has a poor effect in the treatment of SACC, there is a great interest in determining the molecular abnormalities in SACC.

To gain further insight into the molecular mechanism of tumorigenesis, bioinformatics and microarray are widely used in the study of cancers by researchers. However, microarray analysis is not well utilized in improving therapeutic outcomes for SACC. With the hope that doing so will achieve the goal of discovering an effective target-therapy, we identified differentially expressed genes (DEGs) between a low metastatic SACC cell line (ACC-2) and a highly metastatic SACC cell line (ACC-M), which was screened from ACC-2 by combination of in vivo selection and cloning in vitro [15]. Since ACC-2 and ACC-M cells share an identical genetic background except for different metastatic behavior, it is presumed that the DEGs are metastasis-related genes, which play direct or indirect roles in the progression of metastasis. Then the DEGs were analyzed by Gene Ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Then, a protein-protein interaction (PPI) network was built for DEGs. Taken together, the gene signature of metastasis could be helpful to develop novel therapeutic strategies in SACC patients.

Material and methods

RNA extraction and probe preparation

Total RNA from ACC-M and ACC-2 cells was isolated using the TRizol method according to the manufacturer’s (Invitrogen) instructions. RNA quality from each cell line was assessed by visualization of the 28S/18S ribosomal RNA ratio on 1% agarose gel. Total RNA samples were subjected to Human OneArray v6.1 (Phalanx Biotech, Taiwan, China), and all procedures were carried out according to the protocol. Briefly, 0.5 μg of RNA from two cell lines was labeled with a Cy3 fluorophore and labeled RNAs were hybridized at 37°C overnight.

Data preprocessing

The intensity of each probe was processed and normalized by the median scaling normalization method. In order to ensure that a probe was specific for one gene, we eliminated probes with multiple matching gene sequences. When several probes hybridized with transcripts from one gene, we calculated the mean values as the probe value. Normalized intensities were transformed to gene expression log2 ratios between ACC-M and ACC-2.

DEG screening

Because there was no extra replication except for one control group and one experimental group, we applied intensity alignment of probes between ACC-M and ACC-2 to identify DEGs. Genes with log fold change (FC) > 1 were considered to be significant.

GO function and KEGG pathway enrichment analysis

To identify gene functions enriched in ACC-M, we performed GO [16] function enrichment analysis for DEGs in 3 functional ontologies: biological process (BP), cellular component (CC) and molecular function (MF). KEGG pathway [17] enrichment analysis was also performed to identify significant pathways enriched in ACC-M with a platform developed by Feng-He Information Technology Co., Ltd (Shanghai, China). The p-value was calculated by hypergeometric distribution and a pathway with p < 0.01 was considered as significant.
Function annotation for DEGs

To ensure whether DEGs function in transcriptional regulation, transcription factor analysis was employed by mapping DEGs to the intersection between the TRANSFAC [18] and transcription activity term of the GO database. Combined with Tumor Suppressor Gene (TSG) [19] and Tumor Associated Gene (TAG) [20] databases, we also obtained known oncogenes and suppressor genes from identified DEGs.

Construction of PPI network

To study protein-protein association information for DEGs, the STRING database [21] was used to construct the PPI network. The selected protein pairs in PPI with an association score more than 0.9 and the number of nodes more than 3 were products of DEGs.

Results

DEG identification

To identify significant genes between ACC-M and ACC-2, DEG identification was performed. A total of 1128 DEGs were obtained including 448 up- and 680 down-regulated DEGs.

GO function enrichment analysis

To study the function changes in the process of tumor metastasis, we identified over-presented GO categories in BP, CC and MF for both up- and down-regulated DEGs. The top 5 categories for 3 type GO terms are listed in Tables I–III. From the results, up-regulated DEGs were mainly enriched in “reflex” and “synaptic transmission glycinergic” in BP, “extracellular region” and “integral to mitochondrial membrane” in CC, and “inhibitory extracellular ligand-gated ion channel activity” in MF. Down-regulated DEGs were mainly enriched in “adenylate cyclase-activating G-protein coupled receptor signaling pathway” in BP “plasma membrane-related functions” in CC and “G-protein coupled amine receptor activity” in MF.

KEGG pathway enrichment analysis

To gain further insight into the function of DEGs, we used the platform developed by Feng-He Information Technology Co., Ltd (Shanghai, China) to identify the significant pathways. With the selected criteria we finally obtained 9 pathways (Table IV). The up-regulated DEGs were mainly enriched in the “protein processing in endoplasmic reticulum” pathway, while down-regulated DEGs

| GO-ID       | GO-term                                      | Clustered gene numbers | Typical gene symbol | P-value   |
|-------------|----------------------------------------------|------------------------|---------------------|-----------|
| Up-regulated| GO:0060004 Reflex                            | 4                      | GJA1, GLRA1, GLRB,  |
|             |                                              |                        | NPNT                | 0.00026   |
|             | GO:0060012 Synaptic transmission, glycinergic| 2                      | CD274, MMP7,        |
|             |                                              |                        | PRKAR1A, TRPC1WNK4, |
|             |                                              |                        | WNT5A               | 0.00057   |
|             | GO:0046903 Secretion                         | 32                     | CD274, MMP7,        |
|             |                                              |                        | PRKAR1A, TRPC1WNK4, |
|             |                                              |                        | WNT5A               | 0.00057   |
|             | GO:0043030 Regulation of macrophage activation| 4                      | BPI, IL4, SNCA,     |
|             |                                              |                        | WNT5A               | 0.00115   |
|             | GO:0006888 ER to Golgi vesicle-mediated transport | 6                      | INSG1, LaMAN1, SAR1B, |
|             |                                              |                        | SEC23A, SEC23B, SPAST | 0.00120   |
| Down-regulated| GO:0007189 Adenylate cyclase-activating G-protein coupled receptor signaling pathway | 9                      | ADCY1, ADCY3, ADRB1, |
|             |                                              |                        | ADRB2, OPRM1, VIP   | 2.08E-05  |
|             | GO:0051046 Regulation of secretion           | 31                     | IL1A, TGF-β1, CORIN, |
|             |                                              |                        | FAM3D, TNFSF15, TRAF6 | 7.08E-05  |
|             | GO:0002526 Acute inflammatory response       | 13                     | APOL2, CD163, IL1A, |
|             |                                              |                        | IL20RB, VCAM1, VTN  | 7.23E-05  |
|             | GO:0019233 Sensory perception of pain        | 10                     | NTRK1, OPRD1, ADRB1,|
|             |                                              |                        | CHRNBB, P2RX4, VIP  | 8.45E-05  |
|             | GO:0051049 Regulation of transport           | 55                     | IL1A, TGF-β1, BCL2, |
|             |                                              |                        | BEST1, PIK3R1, TRIB3 | 0.00021   |
**Table II.** Gene Ontology function enrichment analysis for both up- and down-regulated differentially expressed genes in Cellular Component (top 5 GO terms were listed)

| GO-ID       | GO-term                                      | Clustered gene numbers | Typical gene symbol                                      | P-value   |
|-------------|----------------------------------------------|------------------------|----------------------------------------------------------|-----------|
| Up-regulated | GO:0005576 Extracellular region              | 70                     | CCL20, CD274, IGSF10, MMP7, NGFR, WNT5A                   | 0.00040   |
|             | GO:0032592 Integral to mitochondrial membrane | 4                      | CPT1A, ETFDH, MFF, TMEM70                                 | 0.00528   |
|             | GO:0044421 Extracellular region part         | 38                     | CCL20, CD274, IL4, MMP26, MMP7, WNT5A                    | 0.00539   |
|             | GO:0031301 Integral to organelle membrane    | 11                     | AAGALT, CPT1A, HSPAS, INSIG1, QSOX1, TMEM70              | 0.00573   |
|             | GO:0005593 FACIT collagen                    | 2                      | COL14A1, COL16A1                                         | 0.00655   |
| Down-regulated | GO:0031226 Intrinsic to plasma membrane      | 62                     | ADAM29, ADCY3, CCR9, CD163, NTRK1, TPO                   | 0.00048   |
|             | GO:0005887 Integral to plasma membrane       | 59                     | ADAM29, ADCY3CCR9, CD163, NTRK1, TAR2                    | 0.00089   |
|             | GO:0044459 Plasma membrane part              | 84                     | ADAM29, ADCY3, CCR9, CD163, NTRK1, OPRD1                | 0.00143   |
|             | GO:0044304 Main axon                         | 6                      | ADORA2A, MYO1D, NCMAPI, ROBO1, SCN8A, SPOCK1             | 0.00253   |
|             | GO:0005576 Extracellular region              | 90                     | CCL16, CD163, IL1A, IL22, TEK, TGF-β1                    | 0.00299   |

**Table III.** Gene Ontology function enrichment analysis for both up- and down-regulated differentially expressed genes in Molecular Function (top 5 GO terms were listed)

| GO-ID       | GO-term                                      | Clustered gene numbers | Typical gene symbol                                      | P-value   |
|-------------|----------------------------------------------|------------------------|----------------------------------------------------------|-----------|
| Up-regulated | GO:0005237 Inhibitory extracellular ligand-gated ion channel activity | 3                      | GABRB2, GLRA1, GLRB                                      | 8.71E-05  |
|             | GO:0016933 Extracellular-glycine-gated ion channel activity | 2                      | GLRA1, GLRB                                             | 0.00253   |
|             | GO:0016934 Extracellular-glycine-gated chloride channel activity | 2                      | GLRA1, GLRB                                             | 0.00253   |
|             | GO:0015276 Ligand-gated ion channel activity  | 9                      | CNGA3, GABRA1, GLRB, P2RX2, TRPC1, TRPC5                | 0.00256   |
|             | GO:0022834 Ligand-gated channel activity      | 9                      | CNGA3, GABRA1, GLRB, P2RX2, TRPC1, TRPC5                | 0.00256   |
| Down-regulated | GO:0008227 G-protein coupled amine receptor activity | 6                      | ADRB1, ADRB2, HTR1A, HTR2A, TAAR2, TAAR6                | 0.00227   |
|             | GO:0004939 β-Adrenergic receptor activity     | 2                      | ADRB1, ADRB2                                            | 0.00298   |
|             | GO:0004867 Serine-type endopeptidase inhibitor activity | 9                      | CPAMD8, OVOS, SERPINA1, SERPINA5, SPINK9, SPOCK1        | 0.00327   |
|             | GO:0004252 Serine-type endopeptidase activity | 12                     | CORIN, F11, PRSS5A, ST14, MST11, PCSK5                  | 0.00328   |
|             | GO:0051537 2 iron, 2 sulfur cluster binding  | 4                      | AIFM3, CISD3, GLRX2, NDUF51                              | 0.00329   |
Identification of differentially expressed genes in salivary adenoid cystic carcinoma cells associated with metastasis

**Function annotation of DEGs**

Combined with genes in Tumor Suppressor Gene (TSG) and Tumor Associated Gene (TAG) databases, we screened known tumor suppressor genes and oncogenes in both up- and down-regulated DEGs. In 25 DEGs enriched in tumor-related “Apoptosis” and “Cytokine-cytokine receptor interaction” pathways, we found that just “Apoptosis” and “Cytokine-cytokine receptor interaction” pathways were associated with tumorigenesis.

**Protein-protein interaction network**

After PPI network construction with the criteria of an association score higher than 0.9 and the number of nodes more than 3, we selected 32 differentially expressed proteins in the network (Figure 1). Moreover, there were 3 DEGs with the number of nodes higher than 10 including 2 up-regulated proteins – phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α (PIK3CA) and protein tyrosine phosphatase, non-receptor type 11 (PTPN11) – and one down-regulated protein, phosphoinositide-3-kinase, regulatory subunit 1α (PIK3R1).

**Discussion**

Salivary adenoid cystic carcinoma is a common malignant tumor that arises from the secretory epithelial cells of salivary glands and has a unique potential for cell invasion and distant migration, particularly to the lungs. To date, there are very few prospective studies of molecular biomarkers which can be used to predict prognosis of SACC or therapeutic response. In this study, DEGs were screened from a highly metastatic cell line (ACC-M) compared with a low metastatic cell line (ACC-2), followed by functional annotation and PPI network construction for DEGs. DEGs were significantly enriched in “Calcium signaling pathway” and “Olfactory transduction”. From the pathway information in the KEGG database, we found that just “Apoptosis” and “Cytokine-cytokine receptor interaction” pathways were associated with tumorigenesis.

**Table IV. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for both up- and down-regulated differentially expressed genes**

| KEGG-ID  | KEGG-term                                         | Clustered gene numbers | Typical gene symbol        | P-value  |
|----------|---------------------------------------------------|------------------------|---------------------------|----------|
| Up-regulated | KEGG:4141 Protein processing in endoplasmic reticulum | 11                      | HSPA2, HSPA5, HSPA8, LMAN1, MAN1A1, PDIA4 | 0.00063 |
| Down-regulated | KEGG:4020 Calcium signaling pathway | 15                      | ADCY1, ADCY3, ATP2B1, GRIN2C, HTR2A, P2RX1 | 0.00047 |
|           | KEGG:4740 Olfactory transduction                  | 24                      | ADCY3, OR1A2, OR1L8, OR2A14, OR2G3, OR2V2 | 0.00120 |
|           | KEGG:4210 Apoptosis                               | 9                       | TGF-β1, IFNA1, NTRK1, PIK3R1, PIK3R2, TNFSF10 | 0.00167 |
|           | KEGG:4080 Neuroactive ligand-receptor interaction | 18                      | ADBR1, ADBR2, CHRN82, F2, GRID1, GRIN2C | 0.00243 |
|           | KEGG:4910 Insulin signaling pathway               | 11                      | G6PC2, IRS1, PCK2, PIK3R1, PIK3R2, SHC2 | 0.00434 |
|           | KEGG:4540 Gap junction                            | 8                       | ADCY1, ADCY3, ADBR1, HTR2A, PDGFC, PLCB | 0.00761 |
|           | KEGG:5414 Dilated cardiomyopathy                  | 8                       | TGF-β1, PRKACG, ADCY1, ADCY3, ADBR1, TNNT2 | 0.00761 |
|           | KEGG:4060 Cytokine-cytokine receptor interaction  | 16                      | TGF-β1, IFNA1, NTRK1, CCL16, CCR9, TNFSF10 | 0.00998 |
sis, cell proliferation and epithelial-mesenchymal transition [22–26]. Previous studies have suggested that TGF-β1 signaling could promote invasion and metastasis of breast cancer and glioma [27, 28]. In addition, it has been proved that overexpression of active TGF-β1 in vivo accelerates lung metastases of transgenic mammary tumors with an effect on tumor size or tumor cell proliferation [29]. Moreover, it was found that TGF-β1 expression was significantly increased in human primary SACC samples with metastasis [30]. Further study showed that TGF-β1 could promote migration and invasion of SACC via TGF-β1/Smad signaling and induce epithelial-mesenchymal transition in normal stromal cells or epithelial cells of SACC [31]. On the other hand, TGF-β1 is a pluripotent cytokine with dual roles and is also considered as a tumor suppressor in tumorigenesis [32]. Inconsistent with the previous study, our microarray test showed that TGF-β1 was down-regulated in a highly metastatic SACC cell line. From the results of pathway enrichment analysis, TGF-β1 was found to be enriched in the “Cytokine-cytokine receptor interaction” pathway. Interaction between the cytokine and cytokine receptor leads to multiple biological responses including prevention of tumor cell apoptosis and cell survival [33]. As a result, we speculate that a decrease of the cytokine TGF-β1, as a tumor suppressor, regulates lung metastasis of SACC through the “cytokine-cytokine receptor interaction” pathway.

NTRK1, as a high affinity receptor for nerve growth factor (NGF), is a member of the neurotrophin receptor family. After binding with NGF, NTRK1 undergoes dimerization and autophosphorylation of tyrosine residues [34]. Then apoptosis, proliferation and differentiation-related proteins including phosphatidylinositol 3-kinase, Rac, Ras and mitogen activated protein kinase, respectively, are activated [35]. These proteins can stimulate apoptosis of tumor cells. In our study, NTRK1 was found to be down-regulated and enriched in the pathway “Apoptosis”. As a result, decreased NTRK1 may contribute to anti-apoptosis of cancer cells and tumorigenesis. Additionally, NTRK2 has been found to be implicated in the pathogenesis of lung cancers [36]. Thus, NTRK2 may be associated with lung metastasis of SACC.

INF-α1, a member of the interferon family, is known as a tumor suppressor gene. A previous study showed that the cytokine mediates its apoptotic effects by inducing expression of a tumor necrosis factor (TNF)-related apoptosis-inducing ligand [37]. Thus, down-regulated INF-α1 may accelerate tumor development. PIK3CA encodes the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K), which has been shown to be expressed in cancers, such as lung and ovarian cancer [38, 39]. Previous studies have indicated that PIK3CA is regulated by transcription factor p53, which is involved in apoptosis and cell cycle arrest [40]. Moreover, inactivation of p53 leads to up-regulation of PIK3CA and appears to be an early step in ovarian carcinogenesis [39]. Furthermore, PIK3CA has been used as a candidate target for inhibition of metastatic tumor growth in bone-metastatic tumors [41]. Consequently, we infer that PIK3CA might be associated with lung metastasis in SACC.

In conclusion, we have identified several DEGs with change of expression in SACC. Transforming growth factor-β1 might be a unique molecule in lung metastasis and could be selected as a candidate target for clinical therapy. NTRK1, IFNA1 and PIK3CA are also associated with tumor development of SACC. Nevertheless, a limitation has to be mentioned. There is no biological repli-
cate in the study. The analysis is merely a qualitative experiment, but it can partly elucidate molecular mechanisms of lung metastasis of SACC. Further experiments are needed, enrolling more biological replicates and verifying the results of bioinformatics.

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81102051), the Natural Science Foundation of Jiangsu Province (Grant No. BK2011659) and the Nanjing University Fundamental Research Funds for the Central Universities (Grant No. 021414340210).

Conflict of interest

The authors declare no conflict of interest.

References

1. Renuhan A, Gleave EN, Hancock BD, Smith P, McGurk M. Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre. Br J Surg 1996; 83: 1750-4.
2. van der Wal JE, Becking AG, Snow GB, van der Waal I. Microvascular density in salivary gland tumours treated in a single centre. Br J Surg 1996; 83: 1750-4.
3. Kim KH, Sung NW, Chung PS, Rhee CS, Park CI, Kim WH. Adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1994; 120: 721-6.
4. Ishibashi H, Shariatcchi T, Nakagawa K, et al. Hypoxia-induced angiogenesis of cultured human salivary gland carcinoma cells enhances vascular endothelial growth factor production and basic fibroblast growth factor release. Oral Oncol 2001; 37: 77-83.
5. Quentin T, Schlott T, Korabiowska M, et al. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 2004; 24: 2745-56.
6. Lloyd RV, Vidal S, Horvath E, Kovacs K, Scheithauer B. Angiogenesis in normal and neoplastic pituitary tissues. Microsc Res Tech 2003; 60: 244-50.
7. Zhang J, Peng B. In vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma. BMC Cancer 2007; 7: 95-101.
8. Zhang J, Peng B, Chen X. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of the salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res 2005; 11: 7343-43.
9. Faur AC, Lazar E, Cornianu M. Vascular endothelial growth factor (VEGF) expression and microvascular density in salivary gland tumors. J Appl Biomed 2014; 12: 418-26.
10. Fujisaka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003; 9: 346-54.
11. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res 2002; 12: 311-20.
12. Blume-Jensen P, Jiang G, Hyman R, Lee KF, O’Gorman S, Hunter T. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility. Nat Genet 2000; 24: 157-62.
13. Chau NG, Hotte SJ, Chen EX, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 2012; 23: 1562-70.
14. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23: 5474-83.
15. Guan X, Qiu W, He RG, Zhou XJ. Selection of adenoid cystic carcinoma cell line highly metastatic to the lung: an experimental study. Int J Oral Maxillofac Surg 1997; 26: 116-9.
16. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-9.
17. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
18. Matys V, Kel-Margoulis OV, Fricke E, et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006; 34: D108-10.
19. Zhao, M, Sun J, Zhao Z. TSGene: a web resource for tumor suppressor genes. Nucleic Acids Res 2013; 41: D970-6.
20. Chen JS, Hung WS, Chan HH, Tsai SJ, Sun HS. In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma. Bioinformatics 2013; 29: 420-7.
21. Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41: D808-15.
22. Ma J, Wang Q, Fei T, Han JD, Chen YG. MCP-1 mediates TGF-beta-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 2007; 109: 987-94.
23. Massagué J, TGFbeta in cancer. Cell 2008; 134: 215-230.
24. Liu C, Wu Z, Sun HC. The effect of simvastatin on mRNA expression of transforming growth factor-beta1, bone morphogenetic protein-2 and vascular endothelial growth factor in tooth extraction socket. Int J Oral Sci 2009; 1: 90-8.
25. Nabrdalik K, Gumprecht J, Adamczyk P, Górczyńska-Kosior S, Zywiec I, Grzeszczak W. Association of rs1800471 polymorphism of TGF-beta1 gene with chronic kidney disease occurrence and progression and hypertension appearance. Arch Med Sci 2013; 9: 230-7.
26. Gawłowska-Marciniak A, Niedzielski JK. Evaluation of TGF-beta1, CCL5/RANTES and sFas/Apo-1 urine concentration in children with ureteropelvic junction obstruction. Arch Med Sci 2013; 9: 888-94.
27. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichtangs J, Weller M. Transforming growth factors beta1 (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via up-regulation of alpha(V)beta(3) integrin expression. Biochem Biophys Res Commun 2000; 268: 607-11.
28. Wei YY, Chen YJ, Hsiao YC, Huang YC, Lai TH, Tang CH. Osteoblasts-derived TGF-beta1 enhance motility and integrin upregulation through Akt, ERK, and NF-kappaB-dependent pathway in human breast cancer cells. Mol Carcinog 2008; 47: 526-37.
29. Muraoka-Cook RS, Kurokawa H, Koh Y, et al. Conditionhal overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 2004; 64: 9002-11.
30. Dong L, Wang YX, Li SL, et al. TGF-beta1 promotes migration and invasion of salivary adenoid cystic carcinoma. J Dent Res 2011; 90: 804-9.
31. Dong L, Ge XY, Wang YX, et al. Transforming growth factor-beta and epithelial-mesenchymal transition are associated with pulmonary metastasis in adenoid cystic carcinoma. Oral Oncol 2013; 49: 1051-8.
32. Bachman KE, Park BH. Duel nature of TGF-[beta] signaling: tumor suppressor vs. tumor promoter. Curr Opinion Oncol 2005; 17: 49-54.
33. Lopez AF, Hercus TR, Ekert P et al. Molecular basis of cytokine receptor activation. IUBMB Life 2010; 62: 509-18.
34. Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 1991; 350: 158-60.
35. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000; 10: 381-91.
36. Terry J, De Luca A, Leung S, et al. Immunohistochemical expression of neurotrophic tyrosine kinase receptors 1 and 2 in lung carcinoma: potential discriminators between squamous and nonsquamous subtypes. Arch Pathol Lab Med 2011; 135: 433-9.
37. Papageorgiou A, Lashinger L, Millikan R, et al. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res 2004; 64: 8973-9.
38. Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008; 214: 347-56.
39. Astanehe A, Arenillas D, Wasserman WW, et al. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci 2008; 121: 664-74.
40. Schlosshauer PW, Cohen CJ, Penault-Llorca F, et al. Prophylactic oophorectomy: a morphologic and immunohistochemical study. Cancer 2003; 98: 2599-606.
41. Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12177-82.